Bolt Biotherapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Bolt Biotherapeutics şirketinin toplam hissedar öz sermayesi $72.0M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $109.3M ve $37.3M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$53.80m
Eşitlik	US$72.03m
Toplam yükümlülükler	US$37.30m
Toplam varlıklar	US$109.33m

Son finansal sağlık güncellemeleri

We Think Bolt Biotherapeutics (NASDAQ:BOLT) Needs To Drive Business Growth Carefully

Mar 15

Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?

May 13

Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?

Dec 01

We're Keeping An Eye On Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Rate

Jul 27

Recent updates

Little Excitement Around Bolt Biotherapeutics, Inc.'s (NASDAQ:BOLT) Revenues As Shares Take 29% Pounding

May 21

We Think Bolt Biotherapeutics (NASDAQ:BOLT) Needs To Drive Business Growth Carefully

Mar 15

Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?

May 13

Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?

Dec 01

Bolt Biotherapeutics: A Promised Follow Up

Aug 26

Bolt Biotherapeutics GAAP EPS of -$0.61 beats by $0.08, revenue of $1.39M beats by $0.89M

Aug 10

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: BOLT 'nin kısa vadeli varlıkları ( $57.1M ) kısa vadeli yükümlülüklerini ( $18.1M ) aşıyor.

Uzun Vadeli Yükümlülükler: BOLT şirketinin kısa vadeli varlıkları ( $57.1M ) uzun vadeli yükümlülüklerini ( $19.2M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: BOLT borçsuzdur.

Borcun Azaltılması: BOLT şirketinin 5 yıl önce borç/öz sermaye oranı 19.7% iken borcu yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: BOLT şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: BOLT un, serbest nakit akışı her yıl % 16.5 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Bolt Biotherapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Bolt Biotherapeutics Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Requirement under Nasdaq Listing Rule 5450(a)(1)

Bolt Biotherapeutics Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Requirement under Nasdaq Listing Rule 5450(a)(1)

We Think Bolt Biotherapeutics (NASDAQ:BOLT) Needs To Drive Business Growth Carefully

Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?

Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?

We're Keeping An Eye On Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Rate

Recent updates

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting

High number of new directors

Bolt Biotherapeutics, Inc. Announces Changes to Its Board of Directors

Consensus EPS estimates fall by 13%

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Bolt Biotherapeutics Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Requirement under Nasdaq Listing Rule 5450(a)(1)

Bolt Biotherapeutics Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Requirement under Nasdaq Listing Rule 5450(a)(1)

Pomerantz Law Firm Announces the Filing of A Class Action Against Bolt Biotherapeutics, Inc. and Certain Officers - BOLT

High number of new directors

Little Excitement Around Bolt Biotherapeutics, Inc.'s (NASDAQ:BOLT) Revenues As Shares Take 29% Pounding

Consensus revenue estimates decrease by 12%, EPS upgraded

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Bolt Biotherapeutics, Inc., Annual General Meeting, Jun 12, 2024

Consensus revenue estimates increase by 44%, EPS downgraded

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

We Think Bolt Biotherapeutics (NASDAQ:BOLT) Needs To Drive Business Growth Carefully

Price target increased by 9.4% to US$5.25

Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating Bdc-1001 in Patients with Her2-Positive Breast Cancer Previously Treated with Enhertu

Consensus revenue estimates increase by 21%

Bolt Biotherapeutics, Inc. Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress

Price target decreased by 7.7% to US$4.80

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?

Bolt Biotherapeutics, Inc. Appoints Laura Berner to Board of Directors

Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$6.40

Bolt Biotherapeutics: A Promised Follow Up

Consensus revenue estimates increase by 36%

Bolt Biotherapeutics GAAP EPS of -$0.61 beats by $0.08, revenue of $1.39M beats by $0.89M

We're Keeping An Eye On Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Rate

Bolt Biotherapeutics, Inc.(NasdaqGS:BOLT) dropped from Russell 2500 Index

Price target decreased to US$11.50

High number of new directors

We're Not Very Worried About Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Rate

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Bolt Biotherapeutics, Inc. Announces Resignation of David Dornan as Chief Scientific Officer, Effective from March 11, 2022

Price target decreased to US$13.67

Bolt Biotherapeutics Doses First Patient with BDC-1001 in Combination with OPDIVO® (nivolumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of HER2-Expressing Solid Tumors

Less than half of directors are independent

We Think Bolt Biotherapeutics (NASDAQ:BOLT) Can Afford To Drive Business Growth

Consensus revenue estimates fall to US$1.00m

Bolt Biotherapeutics: Pioneering A New Class Of Immunotherapies

We're Hopeful That Bolt Biotherapeutics (NASDAQ:BOLT) Will Use Its Cash Wisely

Bolt Biotherapeutics, Inc.(NasdaqGS:BOLT) dropped from Russell 3000E Growth Index

Bolt Biotherapeutics, Inc. announced that it has received $15 million in funding from Genmab A/S

Bolt Biotherapeutics, Inc. Presents Preliminary Results from Phase 1/2 Trial of Lead HER2-targeting Boltbody™ ISAC BDC-1001 at ASCO 2021

Bolt Biotherapeutics, Inc. announced that it expects to receive $15 million in funding from Genmab A/S

Full year 2020 earnings released: US$28.89 loss per share (vs US$15.29 loss in FY 2019)

Bolt Biotherapeutics, Inc. has completed an IPO in the amount of $230 million.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin